Chronic inducible urticaria (CIndU) is a group of diseases characterized by recurrent wheals and/or angioedema induced by specific triggers. Research into its underlying mechanisms remains underdeveloped, historically lagging behind that of chronic spontaneous urticaria (CSU). The profound heterogeneity across CIndU subtypes presents a central challenge, translating into limited and variable efficacy of conventional therapies, including second-generation H1-antihistamines and omalizumab, highlighting the inadequacy of a uniform management strategy. Encouragingly, the clinical development of novel targeted agents, notably anti-KIT biologics and Bruton’s tyrosine kinase (BTK) inhibitors, now offers new promise. Concurrently, the refinement of disease-specific assessment tools and the exploration of biomarkers are facilitating a more personalized approach. This review summarizes recent advances and persistent challenges in CIndU management, advocating for a concerted effort to deepen mechanistic understanding, validate predictive biomarkers, and integrate patient stratification into future clinical trials, thereby paving the way for precision medicine in this field.
Zhang et al. (Fri,) studied this question.